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WntThe organization of the embryonic neural plate requires coordination of multiple signal transduction
pathways, including ﬁbroblast growth factors (FGFs), bone morphogenetic proteins (BMPs), andWNTs. Many
studies have suggested that a critical component of this process is the patterning of posterior neural tissues by
an FGF-caudal signaling cascade. Here, we have identiﬁed a novel player, Dazap2, and show that it is required
in vivo for posterior neural fate. Loss of Dazap2 in embryos resulted in diminished expression of hoxb9 with a
concurrent increase in the anterior marker otx2. Furthermore, we found that Dazap2 is required for FGF
dependent posterior patterning; surprisingly, this is independent of Cdx activity. Furthermore, in contrast to
FGF activity, Dazap2 induction of hoxb9 is not blocked by loss of canonical Wnt signaling. Functionally, we
found that increasing Dazap2 levels alters neural patterning and induces posterior neural markers. This
activity overcomes the anteriorizing effects of noggin, and is downstream of FGF receptor activation. Our
results strongly suggest that Dazap2 is a novel and essential branch of FGF-induced neural patterning.
Published by Elsevier Inc.IntroductionAfter its initial induction from the ectoderm, the developing neural
tissue must be patterned along the anterior–posterior axis. Early
models proposed that this occurred in a two-step process, where an
initial inductive signal – the “activating” signal – instructs naïve
ectoderm to adopt an anterior neural fate. Some of this induced neural
tissue is then “transformed” into more posterior fates, such as
hindbrain and spinal cord, by a second signal (Nieuwkoop, 1952;
Harland and Gerhart, 1997). FGFs, as well as Wnts, retinoids and
insulin-like growth factors may all be important for this regionaliza-
tion of the neural plate (Pownall et al., 1996; Blumberg et al., 1997;
McGrew et al., 1997; Shiotsugu et al., 2004). However, all of these
factors have widespread biological activities, so it has been difﬁcult to
uncouple early requirements for these pathways from speciﬁc roles in
posterior neural patterning. To further complicate matters, it appears
that active repression of these pathways may be required for proper
formation of the anterior brain, suggesting that endogenous “poster-
ior” signals are present throughout the neural plate (Koide et al., 2001;
Niehrs, 2004; Onai et al., 2004).R146, Centre Universitaire,
(A.H. Monsoro-Burq).
Inc.Of these candidate signals, ﬁbroblast growth factors have been
shown to induce posterior neural tissue directly from naïve ectoderm
(Cox and Hemmati-Brivanlou, 1995; Kengaku and Okamoto, 1995;
Lamb and Harland, 1995; Delaune et al., 2005). Consistent with these
data, several studies using dominant-negative FGF receptors sug-
gested that FGF signaling is required for the induction of posterior
neural tissue (McGrew et al., 1997; Pownall et al., 1998; Holowacz and
Sokol, 1999; Ribisi et al., 2000) as well as forebrain fates (Hongo et al.,
1999). FGF8a has also been shown to induce neuronal markers,
including neuronal β-tubulin, as well as an array of neural and neural
crest markers (Hardcastle and Papalopulu, 2000; Monsoro-Burq et al.,
2003; Fletcher et al., 2006). Thus, unlike Noggin, which can only
induce anterior neural tissue, FGFs are able to induce and pattern the
neurectoderm. This suggests a dual role for FGFs, where several
aspects of posterior neural induction and differentiation could occur
as the result of a single molecular cue.
In Xenopus, during patterning of the posterior neural plate, a
caudal homologue, cdx4 (previously known as xcad3), has been
shown to be a direct transcriptional target of FGF's posteriorizing
activity (Isaacs et al., 1998; Haremaki et al., 2003). Cdx proteins, in
turn, can bind to and activate the promoters of posterior hox genes
(Shimizu et al., 2006). In addition, inhibition of Cdx4 activity using
antimorphic repressor mutants or loss of cdx genes in zebraﬁsh has
shown that this activity is required for posterior neural gene
expression (Isaacs et al., 1998; Pownall et al., 1998; Skromne et al.,
2007). These data are consistent with the model that FGF signaling is
27D.D. Roche et al. / Developmental Biology 333 (2009) 26–36necessary for the establishment of posterior neural fate and that this
activity requires at least two steps: immediate early induction of cdx4
followed by subsequent activation of posterior Hox targets. In this
context, Cdx4 may be a direct “transforming” effector.
In this paper, we set out to identify additional molecules thatmight
confer regional identity. We found dazap2 in an expression screen
based on its ability to cause anterior truncations as well as to induce
the spinal cord marker hoxb9 (Grammer et al., 2000). Subsequent
examination showed that in vivo overexpression of dazap2 could
expand the expression of the pan-neural marker nrp1 (Grammer et al.,
2000). Thus, we set out to deﬁne its role in neural patterning further.
Although dazap2 is evolutionarily well conserved, with homo-
logues throughout the vertebrate lineages, little is known about the
activity of this protein family. Thus, the identiﬁcation of the potent
bioactivity of dazap2 provided us with an opportunity to study the
function and requirements for this molecule in vivo. Here, we
demonstrate that dazap2 is necessary and sufﬁcient for the induction
of posterior neural fates in Xenopus. We show that modulating
dazap2 levels shifts the anterior–posterior boundaries within the
neural plate. We then show that unlike FGF-mediated inductions,
posterior fates mediated by Dazap2 action are independent of cdx4
and independent of Wnt/β-catenin signaling. Most interestingly, we
ﬁnd that dazap2 is required for FGF activity. Taken together, this
suggests that dazap2 reveals a novel mechanism for patterning the
posterior neural plate.
Materials and methods
Embryo manipulations and dissection
Xenopus laevis eggs were collected and fertilized using standard
protocols (Sive et al., 2000). Embryos were grown in 1/3× MMR and
staged according to Nieuwkoop and Faber (1994). For blocking FGF
signaling in vivo, we used the chemical inhibitor SU5402 which
inhibits FGFR kinase activity (Mohammadi et al., 1997). A concentra-
tion of 50–80 μM SU5402 was shown to inhibit most neural induction
when applied at mid-blastula stages (Delaune et al., 2005). Thus, for
each experiment, the efﬁciency of the SU5402 treatment was
validated by the analysis of sibling embryos soaked in the inhibitor
solution prior to and during neural induction (stages 7–18) and
stained for sox2. In this regimen, neural induction was strongly
impaired (100%, n=21, not shown). For animal cap experiments, the
vitelline membrane of stage 9 embryos was removed and the
ectoderm of the blastocoel roof was dissected. The explants were
aged in 3/4× NAM until the sibling controls reached the indicated
stages. Then both explants and embryos were collected for RT-PCR
(Sive et al., 2000).
RNA synthesis and antisense morpholino RNA (MO) microinjection
Synthetic messenger RNA was made using the in vitro SP6
mMessage mMachine kit (Ambion). RNA was stored at −80 °C until
thawed on ice prior to injection. The following plasmids were used to
produce mRNA: dazap2 (cs107-dazap2; GenBank Accession
BG354661; FGF8a (cs107-fgf8) (Monsoro-Burq et al., 2003); noggin
(cs2+-noggin) (Mariani and Harland, 1998); cdx4, cdx-VP16 and cdx-
EnR (Isaacs et al., 1998); and nuclear beta-galactosidase (cs2+-nlacZ)
(Rupp et al., 1994). Morpholino oligonucleotides (MO) (Gene Tools)
were designed to bind either the translation initiation region (DZ2-
MO — CTTTATTATTCATAGCTCCGGGTTC) or the splice acceptor (SP-
MO — GGTACTGTCCTGTAGAAAGGAAAGC) on the second exon of the
dazap2 gene (Supplementary Fig. 2). Additionally, a commonly used
Xenopus laevis β-catenin MO (TTTCAACCGTTTCCAAAGAACCAGG)
was acquired from Gene Tools (Heasman et al., 2000). Targeted
mRNA or MO injections were performed in a 10 nl volume into one
blastomere at the 2-cell or 4-cell stage, with nlacZ mRNA co-injectedfor lineage tracing. Embryos were grown in 1/3× MMR until
appropriate stages and then ﬁxed with 3.7% formaldehyde in PBS
for 20 min. Red-gal (Research Organics) was used to reveal
β-galactosidase activity to trace the cells that inherited injected
mRNA (Sive et al., 2000; Monsoro-Burq, 2007). Embryos were then
ﬁxed for an additional 2 h at room temperature or overnight at 4 °C
then dehydrated in several washes of ethanol and stored at −20 °C
until ISH.
Whole-mount in situ hybridization (ISH)
The embryos were gently rehydrated with decreasing amounts of
ethanol (mixed with PBS+0.1% Tween-20). The ISH procedure used a
multi-basket system (Sive et al., 2000), and a fast protocol optimized
for ectoderm and neural tissue (Monsoro-Burq, 2007). Embryos were
then thoroughly washed and AP activity was visualized with BCIP and
NBT (Roche). Digoxigenin-labeled antisense RNA probes were made
from the following plasmids: myoD (Hopwood et al., 1989); sox2
(Grammer et al., 2000); nrp1 (Knecht et al., 1995); otx2 (Lamb et al.,
1993); krox20 (Bolce et al., 1992); hoxb9 (Sharpe et al., 1987); cpl1
(Knecht et al., 1995); sox11; and pax6 (Hirsch and Harris, 1997). Some
embryos were cleared using benzyl benzoate and benzyl alcohol (2:1)
(Sive et al., 2000).
RT-PCR
Proteinase K lysis buffer was used to isolate RNA from embryos and
explants for reverse transcriptase-polymerase chain reaction (RT-PCR)
(Wilson andMelton,1994). A control embryo, not treatedwith reverse
transcriptase, was used to assay the complete degradation of genomic
DNA (lane 2 in RT-PCR gels). All samples used either ef1α or ornithine
decarboxylase (ODC) to normalize the efﬁciency of the RT reaction
and the loading on the gel. STORM phosphoimager analysis software
was used to quantify gel signals. The primer sets are described in
Supplementary Table 1.
Results
Identiﬁcation of Dazap2, a novel molecule involved in neural patterning
To identify novel genes important in patterning the neural plate,
we screened pools of cDNAs for molecules that perturbed expression
of an array of neural markers (Mariani and Harland, 1998; Grammer et
al., 2000). One of the clones we identiﬁed encoded a homologue of
human KIAA0058, also called dazap2 (GenBank accession D31767)
and intriguingly, shifted the anterior–posterior identity of the neural
plate (described below and reported as 81E10 in Grammer et al.
(2000)). Sequence comparisons revealed extensive conservation of
this protein among deuterostomes (Supplementary Fig. 1) while pilot
experiments showed that human and mouse dazap2 mRNA had
similar activities in our assays (data not shown).
The open reading frame of Xenopus dazap2 encodes a protein of
168 amino acids which includes several conserved SH2 and SH3
consensus target sequences, as well as a polyproline rich region
(Supplementary Figs. 1A, B and GenBank accession BG354661). While
such domains suggest that Dazap2 may serve a scaffolding function to
bring other proteins together, they do not address what pathways
Dazap2 interacts with. Several reports have suggested varying
activities for Dazap2, ranging from a role in the inner ear (Yang and
Mansour, 1999), yeast two-hybrid interaction with Daz (Tsui et al.,
2000) and Sox6 (Cohen-Barak et al., 2003), a role in cell adhesion
(Sommerfeldt et al., 2002) to a critical role in stress granule formation
and translational control (Kim et al., 2008). While these data are
intriguing, the cellular function of Dazap2 requires further explora-
tion. The identiﬁcation of Dazap2 in our functional assay provided us
with some insight into the in vivo roles of Dazap2.
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By RT-PCR, dazap2 expression is readily detected at mid-late
blastula stage (Nieuwkoop and Faber stages 8–9) and is maintained
throughout early development (Fig. 1A). By whole-mount hybridiza-
tion, dazap2 staining is seen throughout the animal hemisphere
during blastula stages (not shown). Later, dazap2 expression appears
to be moderately enriched in the neural plate, along the entire length
of the anteroposterior axis (Figs. 1B–F, cleared embryos show
enhanced neural staining at stage 19, Figs. 1E, F). Robust dazap2
expression is observed in the anterior part of the neural tube at late
neurula and tailbud stages, encompassing the eyes, posterior brain,
the anterior spinal cord and the branchial arches (Figs. 1G, G′). AFig. 1. Temporal and spatial expression of dazap2 mRNA. (A) RT-PCR using dazap2
primers shows that dazap2 is expressed during blastula to neurula stages. (B–I) Dazap2
spatial expression pattern was analyzed by whole-mount ISH, using either antisense
(B, C, E–G and H, I) or sense (D and G′) full-length xl-dazap2 probe. Embryos are seen in
dorsal view with anterior to top (B and D, E), posterior view with dorsal on top (C),
lateral view with head to the left (F, G, G′ and H) or ventral view (I). The blue arrow
indicates the blastopore. Embryos hybridized with the sense probe in the same ISH
conditions show no staining at all stages tested (D and G′). (B) At mid-neurula stage 16
(B) and late neural stage 18 (C, posterior view), dazap2 is present in the head folds (red
arrowhead) and throughout the neural plate (black arrow). The staining is enhanced
when neurulae are cleared (stage 19, E and F). By stage 32 (G, G′), tailbud embryos
express dazap2 in trunk and head region, including the brain (red arrowhead) and
spinal cord, the eye, the branchial arches (arrowhead) and the pronephros (green
arrow). A faint staining is found in the dorsal ﬁn (arrow) and the proctodeum (blue
arrow). Cleared stage 44 tadpoles (H, I) express dazap2 in the brain (red arrowhead),
the pronephros (green arrows) and caecum (blue arrow).
Fig. 2. Dazap2 silencing results in a loss of hoxb9 with concomitant posterior shift of
anterior neural markers. Embryos co-injected with Dazap2 SP-MO and lacZmRNAwere
analyzed at stage 18 (shown in dorsal views, with anterior at the top). (A, B) Sox2
expression domainwas only marginally affected. (C, D) Otx2 domainwas expanded and
shifted posteriorly within the neural plate (blue and red lines indicate normal and
shifted posterior limits respectively). (E, F) Krox20 expression (rhombomeres 3 and 5)
also shows a posterior shift in SP-MO injected embryos (blue and red lines indicate
normal and posteriorized rhombomeres 3 and 5 respectively). Expression of hoxb9 is
decreased/lost in injected cells (G, H) and can be rescued when dazap2mRNA (250 pg)
is co-injected with SP-MO (I). The line indicates the sagittal midline.fainter expression is observed in the pronephros and the dorsal ﬁn
(Fig. 1G). Cleared feeding tadpoles showed enhanced expression in
the forebrain, the pronephros and the posterior digestive tract (Figs.
1H, I). These results suggest that Dazap2, a novel small molecule that
displays protein interaction motifs conserved in vertebrates (Shi et al.,
2007), and that has been isolated for its ability to alter anteroposterior
patterning of the embryo (Grammer et al., 2000) is expressed in the
right place and time to play a role in early neural patterning.
Dazap2 is essential for patterning the spinal cord
To assess the in vivo requirements of Dazap2, we used targeted
injections of antisense morpholino oligonucleotides (MO) to block
translation of endogenous Dazap2. We used two different MOs, one
targeting the translational start site (TR-MO), and the second blocking
splicing of the ﬁrst intron (SP-MO), resulting in degradation of the
unspliced pre-mRNA (Supplementary Fig. 2A). Analysis of dazap2
mRNA levels after injection of SP-MO showed a dose-dependent
reduction in endogenous transcripts (up to 60%) (Supplementary Figs.
2B, C). Using these morpholino oligonucleotides allowed us to
knockdown dazap2; effects of the MOs could be rescued by injection
of intact dazap2 mRNA (Fig. 2I) indicating the speciﬁcity of the MOs.
In subsequent experiments, an optimized dose of SP-MO (20 ng/cell)
was co-injected in one blastomere of 4-cell stage embryos along with
lacZ mRNA, unless otherwise noted.
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particularly in the anterior–posterior axis, we examined the require-
ments for dazap2 using a selection of neural markers. We found that
unilateral MO injections resulted in a slightly misshapen neural plate,
based on sox2 expression, but the domain of expression was
essentially normal, suggesting that loss of Dazap2 did not result in
defective neural induction (75%, n=32, Figs. 2A, B). However, we
found expression of the spinal cord marker hoxb9 strongly reduced
(SP-MO 82%, n=71, Figs. 2G, H and TR-MO 75%, n=18). Concurrently,
we found that in these injections, the anterior marker otx2 was
expanded, with a posterior shift compared to the control side (83%,
n=12, Figs. 2C, D). Similarly, rhombomeres 3 and 5, marked by
krox20, also exhibited a posterior shift (51%, n=52, Figs. 2E, F). Of the
embryos that did not exhibit a shift in krox20, many showed a
complete loss in krox20 on the injected side (not shown, 25%, n=52).
These phenotypes could be rescued by co-injection of properly spliced
dazap2mRNAwith SP-MO (250 pg of dazap2mRNA and 20 ng SP-MO,
embryos with rescued hoxb9 expression: 73%, n=66, Fig. 2I,
compared to 82% loss with SP-MO alone). We have next analyzed
the induction of hoxb9 in whole embryos injected with SP-MO by RT-
PCR. Global loss of dazap2 led to a reduction in hoxb9 expression,
while sox2 expression was unaffected (Fig. 3E). Taken together, these
data show that Dazap2 is required for the speciﬁcation of posterior
neural fates in the embryo as well as demarcating the anterior
domains.
Dazap2 is required for FGF posteriorizing activity
Loss-of-function experiments have shown that FGF signaling is
required in the neural plate (Pownall et al., 1996; Isaacs et al., 1998;
Fletcher et al., 2006; Ribisi et al., 2000). This suggested to us that loss
of Dazap2 might perturb FGF pathway activity. We therefore usedFig. 3. FGF8a posteriorizing activity requires Dazap2. Embryos were co-injected with lacZmR
fgf8a (20 ng and 10 pg, respectively, D) into one cell at the 4-cell stage. Stage 18 embryos ar
Compared to control embryos (A), the SP-MO blocks hoxb9 expression on the injected side (B
SP-MO are combined, hoxb9 expression is blocked and no ectopic expression is observed (
40 ng/cell or 20 ng/cell) into two cells at the 2-cell stage, then aged until stage 20 (Ctl, cont
decreased (lanes 3, 4), especially at the highest concentration of SP-MO, while cdx4 and sox2
injected with either dazap2 mRNA (250 pg/embryo, lane 4), SP-MO (40 ng/embryo, lane
+200 pg/embryo, lane 7) or a combination of fgf8a, SP-MO and dazap2 mRNA (40 ng+20
hoxb9 is induced by fgf8a (lane 6) but this induction is blocked in the presence of SP-MO (lan
Fgf8a, cdx4 is robustly induced.several approaches to explore the relationships between FGFs and
Dazap2. First, we activated FGF in vivo while attenuating Dazap2
function using our MOs. As previously reported (Fletcher et al., 2006)
injection of fgf8a mRNA (10 pg) resulted in the anterior expansion of
hoxb9 in vivo (81%, n=27, Fig. 3C) while dazap2 knockdown reduced
the hoxb9 domain (82%, n=71, Fig. 3B). Supporting our hypothesis,
injection of dazap2 SP-MO reversed the fgf8a overexpression pheno-
type, resulting in the reduction of hoxb9 expression in the injected
area (61%, n=18, Fig. 3D). Thus, in vivo, the ability of FGF to increase
hoxb9 expression requires full Dazap2 activity.
Second, in parallel experiments, RT-PCR analysis of FGF injected
ectodermal explants conﬁrmed that SP-MO strongly affected hoxb9
induction by FGF8a (Fig. 3F, compare lane 7 to lane 6). Again, these
effects could be reversed by co-injection of dazap2 mRNA (Fig. 3F,
lane 8). To our surprise, we found that this marked reduction in
hoxb9 was consistently accompanied with increased levels of cdx4
expression (Fig. 3F, lanes 6 and 7). However, this observation in
explants was not reproduced in vivo by in situ hybridization (data
not shown). Because adding back dazap2 mRNA efﬁciently restores
hoxb9 despite the presence of fgf8a mRNA and SP-MO (lane 8), we
are conﬁdent that loss of Dazap2 activity was indeed responsible for
the lack of hoxb9 induction by Fgf8a. Hoxb9 has been shown to be a
target of the FGF-cdx4 transcriptional cascade (Isaacs et al., 1998).
Thus, these results suggest the intriguing possibility that Dazap2
activity, though essential for FGF signals to promote hoxb9 expres-
sion, is acting downstream of or in parallel to the known FGF-Cdx4
signaling cascade.
Cdx4 induction of hoxb9 is Dazap2 independent
To explore this interaction further, we hypothesized that Dazap2
might act in concert with or be required for Cdx4 induction of hoxb9.NA and either dazap2 SP-MO (20 ng, B), fgf8a (10 pg, C) or a combination of SP-MO and
e shown in dorsal views, with anterior to the top (the line indicates the sagittal plane).
, arrow) while Fgf8a induces ectopic hoxb9 expression (C, arrowhead). When fgf8a and
D, arrow). (E) RT-PCR was performed on whole embryos injected with SP-MO (either
rol sibling controls; -RT, no reverse transcriptase control). Hoxb9 expression is strongly
expression remain unaffected. (F) Animal caps were dissected at stage 9 from embryos
5), fgf8a (200 pg/embryo, lane 6), a combination of SP-MO and fgf8a (40 ng/embryo
0 pg+250 pg/embryo, lane 8) at the 2-cell stage (Ni: non-injected caps). At stage 18,
e 7). This loss is rescued by addition of dazap2mRNA (lane 8). In all combinations with
Fig. 4. Cdx4 induction of hoxb9 does not require dazap2. Embryos were injected with
either SP-MO (20 ng, B), cdx4 (250 pg, C), or a combination of SP-MO and cdx4 (20 ng
and 250 pg, respectively, D) into one cell of 4-cell stages (all were co-injected with lacZ
mRNA). Stage 18 embryos are shown in dorsal views, with anterior at the top. As
previously stated, SP-MO blocks the endogenous expression of hoxb9 (B, arrow), but
has no effect on cdx4-induced ectopic expression of hoxb9 (C and D, arrowheads). (E)
Ectodermal explants show that cdx4 induces hoxb9 in Noggin-neuralized caps (lane 7)
and this is not affected by the silencing of dazap2 (lane 8). WE: whole embryo, -RT: no
reverse transcriptase, Ni: not injected.
30 D.D. Roche et al. / Developmental Biology 333 (2009) 26–36FGF induction of posterior fates has been shown to require the
activation domain of Cdx (Isaacs et al., 1998); cdx genes are thought to
act directly on hox genes (Shimizu et al., 2006). Therefore, we chose to
deplete Dazap2 activity in the context of Cdx activity. As previously
shown by Isaacs et al. (1998), cdx4 can ectopically induce hoxb9 in the
anterior neural plate (71%, n=7, Fig. 4C); as before, SP-MO reduces
expression of endogenous hoxb9 (80%, n=60, Fig. 4B). The combina-
tion of Cdx4 gain-of-function and SP-MO still produces ectopic
induction of hoxb9 (64%, n=33, Fig. 4D), indicating that Cdx4 activity
does not rely on Dazap2. Similar results were obtained when Dazap2
SP-MO was co-injected with an activated cdx mRNA (cdx-VP16, cdx4
homeobox fused to VP16 activator domain, (Isaacs et al., 1998, data not
shown). We further substantiated this ﬁnding in an explant assay, by
co-injecting combinations of cdx4 and SP-MO (Fig. 4E). Similar to our
in vivo observations, we found that Cdx4 robustly induced hoxb9 in
noggin-neuralized explants (Fig. 4E, lane 7) and this did not require
full levels of Dazap2 (Fig. 4E, lane 8), again suggesting that Cdx4 acts
in parallel or downstream of Dazap2.
Dazap2 alters neural plate morphology at the expense of anterior tissues
Based on the requirements of Dazap2 seen above, as well as the
initial expression screening phenotype (Grammer et al., 2000), we set
out to determine the functional capacities of Dazap2. To do this, we
injected dazap2mRNA (250 pg) into one blastomere of four-cell stage
embryos; all injections were lineage traced by co-injection of lacZ
mRNA (again, shown in red). When injected dorsally, within or
adjacent to the neural plate, Dazap2 overexpression induced amarked
lateral expansion of the pan-neural markers nrp1 (83%, n=6, Figs.
5A, A′), sox2 (75%, n=24, Figs. 5B, B′), and sox11 (78%, n=9, Figs.
5C, C′). This effect was limited to the dorsal side of the embryo, since
injections targeted outside the neural plate, on the lateral or ventral
side of the embryo, did not induce ectopic neural tissue (100%, n=18,
Figs. 5A″–C″). This expansionwas accompanied by delayed neural fold
elevation. To rule out the possibility that Dazap2 was acting via the
underlying paraxial mesoderm (Mariani et al., 2001), we also
examined myoD expression in these embryos and found no change
(stage 14, Figs. 5D–D″). Therefore, the increase observed in the size of
the neural plate results from Dazap2 directly affecting neural
development.
We next examined the anteroposterior identity of the expanded
neural region. When the injection was targeted dorsally, this region
expressed the spinal cord marker hoxb9 (75%, n=32, Figs. 5E, E′),
suggesting that the expanded neural tissue had acquired a posterior
identity. No ectopic expression was observed when the mRNA was
targeted to more ventral or lateral areas (Fig. 2E″). To bolster this
observation, we also examined anterior markers. Increased dazap2
mRNA greatly reduced cpl1 (anterior neural fold/forebrain, 75%,
n=8, Figs. 5F, F′), otx2 (forebrain, 65%, n=20, see Fig. 6G) and pax6
(forebrain, 100%, n=11, Figs. 5G, G′). Together, these data show that
Dazap2 can expand the neural plate and promote posterior fates at the
expense of the anterior neural tissue.
Dazap2 has potent posteriorizing activity in neural tissues
These observations suggest that elevated dazap2 levels can confer
posterior identity on the embryo.We decided to explore this further in
a sensitized assay, where overexpressed BMP antagonists, such as
Noggin or Chordin, potently induce anterior fates. In vivo, this results
in tadpoles with enlarged head structures and truncated posterior
axes (Smith et al., 1993; Sasai et al., 1995). In ectodermal explants,
Noggin induces neural tissue of an anterior character (otx2) but not
more posterior markers (Lamb et al., 1993; Fig. 6A, lane 6). As
expected, Noggin activated the pan-neural marker sox2 as well as the
anterior marker otx2, but not more posterior markers (midbrain: en2,
spinal cord: hoxd1 and hoxb9) (Fig. 6A, lane 6). In contrast, Dazap2induced the full array of anterior–posterior markers including otx2,
en2, hoxd1 and hoxb9 (Fig. 6A, lane 4), while it only marginally
activated sox2. The effect on hoxd1 and hoxb9 is comparable to FGF8a
activity in animal caps (lane 5), but Dazap2 does not activate cdx1,2 or
4 genes like FGF8a. The combination of dazap2 and Noggin injection
resulted in the co-expression of forebrain (otx2), midbrain (en2) and
spinal cord (hoxd1 and hoxb9) markers in sox2-positive animal caps
(Fig. 6A, lane 7). Again, none of the caudal related genes (cdx1, cdx2
and cdx4) were activated by Dazap/Noggin, suggesting that induction
of the spinal cordmarkers by Dazap is independent of FGF-cdx activity.
In vivo, Dazap2 induces posterior tissues (hoxb9), at the expanse of
anterior fates (cpl1, pax6). Surprisingly, in addition to the induction of
posterior markers (hoxb1, hoxb9, en2) in the animal cap explants, we
have consistently obtained induction of otx2, a forebrain marker.
Moreover, this induction is dose-dependent and parallels hoxb9
induction (Fig. 6B, lanes 4–6). However, in animal cap explants
neuralized by noggin, we observed two groups of genes with distinct
responses to increasing doses of dazap2. The posterior markers (en2,
hoxb1, hoxb9) were induced robustly when Dazap2 activity increases
(Fig. 6B, lanes 8–10). In marked contrast, otx2 induction is attenuated
when Noggin is combined with increasing doses of Dazap2, indicating
31D.D. Roche et al. / Developmental Biology 333 (2009) 26–36that Dazap2 interferes with the anteriorizing noggin action in the
neural context (Fig. 6B, lanes 8–10).
We also found that Dazap2 could modulate the response to Noggin
activity in whole embryos. Embryos were injected into the animal
hemisphere by targeting a dorsal blastomere at 4-cell stage, with lacZ
alone (100 pg, Figs. 6C–E), dazap2 mRNA (250 pg, Figs. 6G–I), noggin
mRNA (25 pg Figs. 6K–M) or a combination of dazap2 and noggin
mRNAs (Figs. 6O–Q). Dazap2 injection resulted in reduced otx2 and
krox20 expression in neurula embryos (65%, n=34 and 100%, n=52
respectively, Figs. 6G, H). This suggests that, although Dazap2 is
sufﬁcient to induce both anterior and posterior neural markers in the
explant as say, additional cues, such as neuralization, modulate this
activity in the embryo or in neuralized explants and favor the
posteriorizing effects. Hence, the induction of hoxb9 in the explant
assay, both alone and in combinationwith Noggin (Fig. 6A, lanes 4 and
6), can be related to the ectopic expression in the anterior neural plateFig. 5. Dazap2 gain-of-function expands the neural plate and induces a posterior identity at
(A′–H′, red arrow) or ventrally (A″–E″, green arrow). Embryos were analyzed at stages 16–1
injected side is on the right, injected cells are marked by the red nuclear stain. General neu
expressed in or around the neural plate but not when dazap2 is injected on the ventral si
injections. Hoxb9 (E–E″) is strongly ectopically expressed in dorsal but not ventral targete
decreased when dazap2 is targeted to the anterior neural plate (arrows, bar indicates the m(75%, n=32, Fig. 6G). Excess Noggin results in enlarged heads and a
reduced trunk ((Smith and Harland, 1992); 86% n=15, data not
shown) as well as expanded otx2 and krox20 domains (3/4 and 5/6
respectively, Figs. 6K, L), along with reduced hoxb9 expression (4/4,
Fig. 6M). When injection of noggin and dazap2 is combined, it appears
that Dazap2 activity is antagonistic to and overcomes that of Noggin,
with otx2 and krox20 expression levels comparable to dazap2 injected
embryos while hoxb9 is ectopically induced (Figs. 6O–Q, n=3/4,
n=5/5, and n=5/5, respectively). This is clearest in cells located in
the lacZ-traced area as the effects on otx2 and krox20 outside of this
area are due to the diffusible activity of Noggin. These data suggest
that Noggin anteriorizing activity is superseded in the cells that
overexpress Dazap2, and results in reversal of the Noggin phenotype.
Since we had not observed Dazap2 induction of neural markers
outside the neural plate in the whole embryo (Fig. 5), we conclude
that Dazap2 effects seen in ectodermal explants are modulated bythe expense of anterior fates. Injections of dazap2 mRNA were targeted either dorsally
8 (shown in dorsal views with anterior at the top (A–E″), or frontal views (F–H′)). The
ral markers nrp1 (A–A″), sox2 (B–B″) and sox11 (C–C″) are expanded when Dazap2 is
de of the embryo. MyoD (D–D″) expression is not affected by either dorsal or ventral
d injections. The expression of anterior neural markers cpl1 (F, F′) and pax6 (G, G′) is
idline).
Fig. 6. Dazap2 has potent posteriorizing activities in neuralized tissues. (A) Both cells of 2-cell stage embryos were injected with the following mRNAs: NI, non-injected; dazap2 (DZ2, 250 pg/embryo); fgf8a (F8a, 100 pg/embryo); noggin
(12.5 pg/embryo); or combination as indicated above lanes. RT-PCR analysis shows expression of a complete range of anterior and posterior markers inwhole embryo (WE, line 1) but none in the NI caps (lane 3). Dazap2 and fgf8a both induce
posterior genes hoxd1 and hoxb9, but Dazap2 also activates otx2 and en2 while fgf8 activates cdx1, 2 and 4 (lanes 4, 5). Upon neuralization by noggin (indicated by sox2 expression), animal caps express anterior markers only (otx2, lane 6).
Dazap2 and noggin co-injections (lane 7) induce a complete range of anterior and posterior markers (but not cdx1, 2 or 4), while Fgf8 and Noggin co-injections only partially posteriorize the explants (en2 induction, lane 8). (B) A range of
dazap2mRNA (125 pg/cell, 50 pg/cell, 10 pg/cell or 2 pg/cell) alone or in combinationwith noggin (12.5 pg/cell) was injected into both cells of 2-cell stage embryos. Explants were dissected at stage 9 from these embryos and aged until stage
18. Decreasing levels of dazap2, alone or in combination, show a decrease level of induction of en2, hoxd1 or hoxb9. This is the opposite effect for otx2, which shows a decrease of induction alone but an increase induction in combination with
noggin. Additionally, sox2 induction requires noggin. For in vivo analysis, embryos were injected at 4-cell stage with lacZ (100 pg/cell, C–E), dazap2 (250 pg) and lacZ (G–I), noggin (25 pg) and lacZ (K–M) or a combination of dazap2, noggin
and lacZ (O–Q). Dazap2 injected embryos show a reduction of otx2 and krox20 expression (arrow) and ectopic expression of hoxb9 (arrowhead) in the anterior neural plate at stages 16–18 (G–I). Noggin-injected embryos show an increase in
both otx2 and krox20 (arrow), and a decrease in hoxb9 expression (arrowhead) (K–M). The combination of dazap2 and noggin results in rescued otx2 and krox20 expression in injected cells (arrows) and hoxb9 expression is activated
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are well described by the neuralized animal explants and by in vivo
injections. In both these situations, Dazap2 antagonized Noggin
anteriorization of neural cells and favors posterior fates.
Dazap2 and FGF8a have different posteriorizing activities
Because of the requirement for Dazap2 in FGF posterior activity
(Fig. 3), we also compared FGF8a and Dazap2 activities in explant
assays (Fig. 6A, lanes 4 and 5). fgf8a alone robustly induced posterior
markers cdx1, cdx2 and cdx4 and spinal cord markers hoxd1 and
hoxb9 but not the more anterior markers (Fig. 6A, lane 5). However, in
combination with Noggin (Fig. 6A, lane 8), fgf8a failed to induce
posterior markers. Instead, the midbrain marker en2 was induced,
indicating the mild posteriorizing effect of FGF8a in the presence of
Noggin. This differed greatly from our results on combined Dazap2/
Noggin treatment (Fig. 6A, lane 7). Again, we found amongst the
posterior markers, that these differences appear to be at the level of
cdx1, 2 and 4, which are robustly induced by fgf8a but not by dazap2
(compare Fig. 6A, lanes 4 and 5). This suggested to us that Dazap2 has
a potent cdx-independent posteriorizing activity.
Loss of FGF signaling in the neural plate is rescued by Dazap2 activity
Because of the loss-of-function and gain-of-function interactions
described above, we hypothesized that Dazap2 activity would be
downstream of FGF and in parallel to or downstream of cdx4. If this
were the case, dazap2 overexpression should bypass loss of FGF
signaling in the neural plate. To test this, we used the chemical
inhibitor SU5402 to block FGF signal transduction (Mizuseki et al.,
1998; Delaune et al., 2005). Prior studies had shown that SU5402
treatment of Xenopus embryos during early stages disrupted meso-
dermal and neural development (Delaune et al., 2005). We used these
data to ensure the potency of our SU5402, by treating sibling controls
at stage 8 (data not shown). For our experiments, we bypassed these
early effects by treating embryos at the end of gastrulation (stage 12),
which did not affect neural induction (assayed by sox2 expression,
Figs. 7A–B). We thus focus speciﬁcally on the role of FGF in posterior
neural plate patterning. After verifying that dazap2 gain-of-function
does not activate hoxb9 precociously (not shown) we challenged the
ability of Dazap2 to promote posterior fates in the absence of FGF
signaling. Embryos were injected with dazap2 mRNA then treatedFig. 7. Loss of FGF receptor signaling in the neural plate is rescued by dazap2. Uninjected con
stage) (co-injected with lacZ mRNA, A′–D′) were treated with either DMSO (1%, carrier con
anterior at the top. Uninjected embryos show no change in sox2 expression after SU5402 tre
when compared to sibling controls (A and C, respectively). Dazap2mRNA injected embryos s
expression hoxb9 (C′ and D′) when treated with either DMSO or SU5402.with either SU5402 or DMSO (vehicle) starting at stage 12. At stage 18
both SU5402-treated and control sibling embryos exhibited normal
sox2 domains (94%, n=16, Figs. 7A–B) while dazap2 injected embryos
showed enlarged neural plates both in the presence (Fig. 7A′) or
absence of FGF signaling (Fig. 7B′). Although SU5402 treatment at
these stages resulted in an almost complete loss of hoxb9 expression
(59%, n=22, Fig. 7D), in this context, dazap2 still induced ectopic
hoxb9, on the injected side, thus bypassing a requirement for FGF
receptor signal during neural plate posterior patterning (100%, n=12,
Fig. 7D′).
Dazap2 activity is cdx4 independent
FGF induction of hoxb9 is thought to be a direct consequence of
Cdx4 activation (Shimizu et al., 2006). Since we have shown that
Dazap2 does not induce cdx1, 2 or 4 (Fig. 6), we tested the assumption
that cdx4 would be dispensable for Dazap2 activity. To do this, we
blocked hoxb9 activation using the antimorphic construct cdx-EnR
(Isaacs et al., 1998) (57%, n=7, Fig. 8C), which fuses the cdx4
homeodomainwith a repressor domain from engrailed and blocks cdx
targets. Reinforcing our hypotheses, Dazap2 still efﬁciently increased
hoxb9 expression, indicating that Dazap2 activity does not require a
Cdx activating function (89%, n=9, Figs. 8B, D). RT-PCR experiments
conﬁrmed these results (Fig. 8E, lanes 4 and 5). This ruled out the
possibility that Cdx4 might be downstream of Dazap2 (as suggested
above, Fig. 4). Since Cdx and Dazap2 are not reciprocally required for
hoxb9 induction, we conclude that they are acting independently, and
in parallel, downstream of FGF.
Together, our data suggest that FGF induction of posterior neural
tissues can occur via two distinct pathways, one mediated by the
caudal-like transcription factors and the other by Dazap2.
Dazap2 induces hoxb9 in a Wnt/β-catenin independent manner
FGF activity on induction of spinal cord marker depends on active
Wnt signaling. In the presence of a dominant-negative form of Wnt8,
hoxb9 induction by bFGF is lost in animal cap explants. Moreover,
analysis of the cdx4 gene regulatory sequences shows conserved LEF/
TCF elements that are essential for the response to FGF.We thus tested
whether Dazap2 activity on hoxb9 is also dependent on canonical Wnt
signaling. We co-injected either fgf8a mRNA and β-catenin morpho-
lino (20 ng/cell) or dazap2mRNA and β-catenin morpholino inwholetrol embryos (A–D) or embryos injected with dazap2 mRNA (250 pg, one cell at 4-cell
trol) or SU5402 (80 μM) at stage 12. Stage 18 embryos are shown in dorsal views, with
atment (B), in contrast, hoxb9 expression was strongly reduced (D) in treated embryos,
how both an expansion (arrow) of sox2 expression (A′ and B′) and ectopic (arrowhead)
Fig. 8. Dazap2 activity is Cdx4-independent. mRNAs for dazap2 (250 pg, B), cdx-EnR
(250 pg, C) or a combination of dazap2 and cdx-EnR (250 pg each, D) were injected into
one cell of 4-cell stage embryos (all were co-injected with lacZ mRNA). Stage 18
embryos are shown in dorsal views, with anterior at the top. Dazap2 injections induce
ectopic hoxb9 expression (B, arrowhead) while cdx4-EnR overexpression blocks hoxb9
induction (C, arrow). Combined Dazap2 and cdx-EnR injection results in robust hoxb9
induction (D, arrowhead). Parallel experiments in explants (E) show that Dazap2
induces hoxb9 either alone (lane 4) or in the presence of Cdx-EnR (lane 5).
Fig. 9. Dazap2 activity does not depend on canonical WNT signaling. (A) RT-PCRwas perform
with β-cateninMO (either 40 ng/cell or 60 ng/cell) into two cells at the 2-cell stage, animal ca
no reverse transcriptase control; Ni, non-injected explant control). Hoxb9 expression is lost
(lane 4). (B)When the experiment is repeated using Dazap2 (125 pg/cell), β-cateninMO is u
lanes 5 and 6).
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sibling embryos conﬁrmed that the β-cateninMOwas fully effective at
this dose. While the presence of the β-catenin MO blocked FGF8a
induction of cdx4 (not shown) and hoxb9 (Fig. 9A), Dazap2 still
robustly induced hoxb9 in the absence of β-catenin-dependent
signaling (Fig. 9B). These ﬁndings conﬁrm that while FGF function
depends on both Wnts and Dazap2, Dazap2 acts independently of
both cdx genes and canonical Wnt activation.
Dazap2 sensitizes cells to FGF signaling
Finally, we addressed how Dazap2, which is ubiquitously
expressed in the neural plate during neural patterning (Fig. 1), could
promote posterior fates (Figs. 5, 6).We reasoned that Dazap2 provides
some signal ampliﬁcation, by promoting posterior fates in response to
low FGF signal levels. We tested this hypothesis by injecting very low
doses of FGF in animal cap explants, in combination with increasing
levels of dazap2 mRNA (Fig. 10). We found that a minimum dose of
10 pg/cell of fgf8a mRNA is needed to elicit hoxb9 expression in
animal caps (lanes 4–6). A very low dazap2 mRNA dose (2 pg/cell)
does not change this response (lanes 7–9). However, when dazap2
mRNA is injected at a slightly higher dose (10 pg/cell), which alone
does not induce hoxb9, the cells potently respond to sub-threshold
doses of fgf8a (2 pg/cell and 0.1 pg/cell respectively, lanes 10–12). As
a positive control, injections of dazap2 mRNA (50 pg/cell), which
induce hoxb9 alone, show potent cooperation with fgf8a (10 pg, lanes
13–15). We conclude that Dazap2 promotes sensitivity of the cells to
FGF signals, and thus could participate in interpreting the posterior
FGF gradient present in vivo.
Discussion
Dazap2 is a novel molecule in posterior patterning
Setting up regional territories in the embryo is critically important
for proper development of an animal. In this report, we identify and
characterize Dazap2, which plays an integral role in establishment of
anterior–posterior boundaries within the neural plate. Many studies
have identiﬁed signaling pathways that are important in regional
speciﬁcation of the neural plate. However, fewer studies have
implicated direct positive regulators of spinal cord identity. This
report identiﬁes a new “transforming” factor that directly induces
spinal cord markers; in the absence of Dazap2, posterior markers are
lost while anterior markers are expanded (Fig. 2). Increasing the levels
of Dazap2 in vivo results in a reciprocal increase in spinal cord at theed using whole embryos injectedwith fgf8a (100 pg/cell) either alone or in combination
ps were dissected and then aged until stage 19 (WE, whole embryo sibling controls; -RT,
at both concentrations of β-catenin MO (lanes 5 and 6) when compared to Fgf8a alone
nable to block Dazap2 induction of HoxB9 expression (compare lane 4, with co-injection
Fig. 10. Dazap2 activity potentiates induction of posterior fate by FGF8a. RT-PCR was performed using whole embryos injected with a range of fgf8a (0.1 pg/cell, 2 pg/cell and
10 pg/cell) alone or in combination with dazap2 (either 2 pg/cell, 10 pg/cell or 60 pg/cell) into two cells at the 2-cell stage, animal caps were dissected and then aged until stage 18
(WE, whole embryo control sibling; -RT, no reverse transcriptase control; Ni, n`on-injected explant control). Hoxb9 expression is observed only at the highest concentration of fgf8a
alone (lane 6) or in combination with 2 pg/cell dazap2 (lane 9). When fgf8a is combined with 10 pg/cell or 50 pg/cell of dazap2, lower levels are required to induce hoxb9 (lane 11
and lanes 13,14, respectively).
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plays a role not only in speciﬁcation of the spinal cord, but also in
protecting caudal tissues from anteriorizing signals.
To address this potential protective activity, we assessed the ability
of Dazap2 to re-pattern strongly anteriorized neurectoderm. We
found that Dazap2 neutralizes the excess anterior domain observed in
Noggin-injected embryos: Dazap2 can block the Noggin-induced
expansion of otx2 and krox20 expression while promoting hoxb9
expression in vivo; this activity is cell-autonomous and also observed
in neuralized explants (Fig. 6). Thus, we conclude that Dazap2 exerts a
potent posteriorizing inﬂuence in vivo and this activity can protect
against excess anteriorizing signals.
Dazap2 is required for FGF-mediated posterior patterning
Many studies have enriched our knowledge of how anterior–
posterior patterning of the neural plate is achieved: BMP, WNT and
Nodal inhibitors secreted from the Spemann organizer establish the
rostral neural fates during gastrulation while FGF, WNT and retinoids
cooperate to patternmore caudal fates of the hindbrain and spinal cord
(for review, see Niehrs (2004)). In particular, FGF signaling is essential
for spinal cord formation, and acts via caudal homologues to activate
posterior hox genes (Pownall et al., 1996; Isaacs et al., 1998). In loss-of-
function analyses, both in vitro and in vivo, we demonstrate that
Dazap2 function is essential for FGF pathway induction of posterior
hox genes in a caudal-independent mechanism (Fig. 3). We observed
that while Dazap2 was required for activation of hoxb9, it was not
required for induction of the FGF target cdx4 (Fig. 3F). This raised the
possibility that loss of dazap2does not block the FGF signaling itself but
instead changes the Hox responsiveness (to hoxd1 and hoxb9) of the
affected tissues, either downstream or in parallel to Cdx4.
To test the relationship between Cdx4 and Dazap2, we used Cdx4
gain-of-function experiments to induce hoxb9 expression. In contrast
to ectopic hoxb9 induced by FGF, Cdx4 induced hoxb9 could not be
blocked by Dazap2 SP-MO (Fig. 4). Conversely, blocking Cdx4
transcriptional activation results in hoxb9 loss; this loss is efﬁciently
rescued by increasing levels of Dazap2 (Fig. 8). These results
suggested that Dazap2 and Cdx4 exert parallel and independent
posteriorizing activities. Thus, in the normal embryo, levels of Dazap2
and Cdx4 create a critical threshold for FGF responsiveness and
activation of posterior hox genes. Increase of either Dazap2 or Cdx4
overrides the requirement for the other, while loss of either then
results in a loss of hoxb9 expression. Taken together, our data provide
evidence that Dazap2 is an essential component of FGF-induced
neural patterning and acts in parallel to Cdx4. Moreover, dose-
response experiments demonstrate that Dazap2 sensitizes the cellsto low levels of FGF signaling (Fig. 10), suggesting that Dazap2
participates in ﬁne-tuning the interpretation of the posteriorizing FGF
gradient during neural patterning.
Dazap2 is sufﬁcient to induce posterior markers in the absence of FGF
receptor activation
Our analyses also suggested that Dazap2 could mimic FGF function
in neural posteriorization. The data above implied that Dazap2 acts
downstream of FGFs, in parallel to the caudal genes. However, we
wanted to exclude the possibility of reciprocal requirements for FGF in
Dazap2 activity. To do this, we blocked expression of hoxb9 using a
chemical inhibitor of FGF receptors; we found that in this context,
Dazap2 was sufﬁcient to rescue expression of hoxb9 (Fig. 7). Thus, we
conclude that Dazap2 is a required component of FGF posteriorizing
activity, acting downstream of FGFR activation.
Finally, in order to investigate whether this novel parallel pathway
can interact with other posteriorizing signals, we have addressed
whether canonical Wnt signaling is required for Dazap2 activity. Such
a requirement was previously shown to be essential for FGF activity on
hoxb9 (Kudoh et al., 2002). Here we show that blocking the canonical
Wnt pathway at the level of β−catenin does not affect the potent
induction of hoxb9 by Dazap2 (Fig. 9). These observations show that
the mechanisms mediated by FGF and Wnt in neural posteriorization
are distinct from those of Dazap2 and suggest that as yet unchar-
acterizedmolecular mechanisms activated by Dazap2 confer posterior
identity.
In summary, using gain and loss-of-function strategies, we showed
that Dazap2 levels control the balance between anterior and posterior
neural fates. Since dazap2 expression is not restricted to the posterior
part of the embryo at the time of neural patterning, it is unlikely that
Dazap2 works directly as a posteriorizing signal; instead, our data
shows that Dazap2 activity is important to adapt cellular responses to
positional cues. Elevated Dazap2 levels increase the domain respond-
ing to posterior signals, resulting in expansion of spinal cord fate,
while loss of Dazap2 restricts the posterior domain, resulting in an
expansion of anterior brain structures at the expense of the spinal
cord and hindbrain domains. These ﬁndings shed light on a novel
mechanism formodulating FGF responsiveness in the neural plate and
raise the intriguing possibility that Dazap2 provides a permissive
environment posterior Hox gene expression.
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